FOXO4-DRI dosing (preclinical regimens)
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
FOXO4-DRI is given subcutaneously in short courses (a senolytic pattern, a few consecutive days, with the cycle repeated a few times per year). The figures below are a generalized reference drawn from preclinical work (Baar et al., 2017) and open community protocols; no human clinical trials exist.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (3 consecutive days) | 0.5–1 mg subcutaneously per day | Starting dose |
| Main cycle (3 consecutive days) | 2–2.5 mg subcutaneously per day | Increase if needed |
| Cycle ceiling; cycle repeated 2–3x per year | up to 5 mg subcutaneously per day | Maximum in this schedule |